Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer

Journal of Clinical Oncology

Volumn 25, Issue 22, 2007, Pages 3224-3229

  de Gramont, Aimery ^a   Buyse, Marc ^a   Abrahantes, Jose Cortinas ^a   Burzykowski, Tomasz ^a   Quinaux, Emmanuel ^a   Cervantes, Andres ^a   Figer, Arie ^a   Lledo, Gérard ^a   Flesch, Michel ^a   Mineur, Laurent ^a   Carola, Elisabeth ^a   Etienne, Pierre Luc ^a   Rivera, Fernando ^a   Chirivella, Isabel ^a   Perez Staub, Nathalie ^a   Louvet, Christophe ^a   André, Thierry ^a   Tabah Fisch, Isabelle ^a   Tournigand, Christophe ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34548242294     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.4380     Document Type: Article

References (20)

1. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
2. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
3. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
4. Goldberg RM, Sargent DJ, Morton RF, et al: A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
6. Cunningham D, Humblet Y, Siena S, et al: A randomised comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
7. Maindrault-Goebel F, Tournigand C, Andre T, et al: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15: 1210-1214, 2004
8. Tournigand C, Cervantes A, Figer A, et al: FOLFOX4 or FOLFOX7 with oxaliplatin stop-and-go in advanced colorectal cancer: Optimox1, a random-ised GERCOR study. J Clin Oncol 24:394-400, 2006
9. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
10. Schoenfeld D: Partial residuals for the proportional hazards regression model. Biometrika 69:239-241, 1982
11. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
12. Vaupel JW, Manton KG, Stallard E: The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography 16:439-454, 1979
13. Cook JR, Stefanski LA: Simulation-extrapolation estimation in parametric measurement error models. J Am Stat Assoc 89:1314-1328, 1984
14. Caroll RJ, Küchenhoff H, Lombard F, et al: Asymptotics for the SIMEX estimator in nonlinear measurement error models. J Am Stat Assoc 91: 242-250, 1996
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Buyse M, Piedbois P: On the relationship between response to treatment and survival. Stat Med 15:2797-2812, 1996
17. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomised GERCOR study. J Clin Oncol 22:229-237, 2004
18. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
19. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441-9442, 2005
20. DiLeo A, Bleiberg H, Buyse M: Is overall survival a realistic primary endpoint in advanced colorectal cancer? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with irinotecan. J Clin Oncol 21:2045-2047, 2003